- In March 2024, Archean Chemical Industries commenced operations of its bromine derivative production facility, successfully commissioning Phase 1 of the project. This initiative strengthens the company's position in the bromine derivatives market and addresses the growing global demand for specialty bromine-based products
- In November 2023, Lupin Limited, a global pharmaceutical company, launched Rocuronium Bromide Injection in the U.S. market after receiving FDA approval through Caplin Steriles Limited for its ANDA. Available in 50 mg/5 mL and 100 mg/10 mL multi-dose vials, this product serves as a generic alternative to Zemuron, widely used as an adjunct to general anesthesia for rapid sequence intubation and muscle relaxation during surgeries. The launch is expected to capture a share of the U.S. market, where Rocuronium Bromide had estimated annual sales of USD 54 million
- In January 2023, ICL introduced BromoQuel, an innovative neutralization system designed to handle both liquid and gas phases. The system's key component is an extinguisher formulated with a specialized bromine complexing agent, enhancing safety and operational efficiency in industrial applications involving bromine derivatives
- In August 2021, the Environmental Protection Agency (EPA) issued updated guidelines regarding the use of methyl bromide for quarantine and pre-shipment fumigation of logs stored in ships' holds, with new regulations taking effect from January 1, 2023. This regulatory update aims to ensure safer, more environmentally responsible usage of bromine-based fumigants across global shipping operations
